NanoViricides, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015 (filed September 14, 2015). The filing is an annual report, not a report for calendar 2014 Q4. Comparisons below are primarily with the year ended June 30, 2014.
Business context
NanoViricides is a development-stage antiviral drug company with no approved products and no revenue. Its candidates use licensed nanomedicine technology; programs include injectable and oral FluCide, topical HerpeCide, eye drops, HIVCide and DengueCide. All programs remained preclinical. Injectable FluCide and HerpeCide were prioritized for IND-enabling work. The company relies on TheraCour Pharma for core technology and materials, and on outside organizations for much testing.
Financial results and position
| Metric | FY2015 / June 30, 2015 | FY2014 / June 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $7.063 million | $8.667 million |
| Operating loss | $7.063 million | $8.667 million |
| Net loss | $2.198 million | $13.602 million |
| Basic / diluted loss per share | $0.04 / $0.09 | $0.27 / $0.27 |
| Cash and cash equivalents | $31.468 million | $36.697 million |
| Working capital | $31.081 million | $36.437 million |
| Total assets | $44.187 million | $43.860 million |
| Total liabilities | $12.401 million | $20.491 million |
| Stockholders’ equity | $31.786 million | $23.369 million |
Operating cash use was $6.212 million, versus $6.334 million in FY2014. Net investing cash use was $5.760 million; property and equipment purchases were $6.760 million, partly offset by a $1.000 million collateral advance. The company acquired its Shelton facility from related party Inno-Haven for reported acquisition and closing costs of approximately $4.304 million. Property and equipment, net, rose to $11.963 million from $5.497 million.
Operating expenses included $3.660 million of R&D and $3.403 million of general and administrative expense. No revenue or gross margin was reported, so commercial margins are not applicable. The net loss narrowed sharply, but FY2015 included an $8.529 million noncash gain from changes in derivative fair value; this was the main driver of the improvement, not revenue growth. Interest expense was $2.650 million, with an additional $1.175 million of debenture discount amortization.
Long-term liabilities were $11.800 million, including Series B and C convertible debentures, derivative liabilities and deferred interest. The company had $6 million of Series B debentures bearing 8% interest and a $5 million Series C debenture bearing 10% interest, both associated with director Milton Boniuk. The filing reports $600,895 of current liabilities. No cash dividend was paid or expected in the foreseeable future.
Material changes and unusual items
- Cash declined by $5.229 million during FY2015. Financing cash inflow was $6.743 million from exercise of old warrants; the company also received $5 million for the Series C debenture in July 2014, although that subscription had been received before the prior year-end and was recorded as a deposit at June 30, 2014.
- The company issued 571,433 common shares as Series B debenture interest, recording $1.503 million of interest expense. Common shares outstanding increased to 57.242 million from 54.621 million.
- FY2015 derivative accounting produced a $8.529 million gain, compared with a $1.443 million loss in FY2014. These fair-value movements are noncash and materially affect reported net loss.
- The auditor change to EisnerAmper followed discovery that prior-year derivative effects on certain warrants and debentures had not been accounted for correctly. Prior annual and quarterly filings were amended and restated. The FY2015 financial statements received an unqualified audit opinion, but the auditor issued an adverse opinion on internal control over financial reporting.
- The company acquired its Shelton R&D and cGMP-capable facility from Inno-Haven, controlled by Chairman Anil Diwan. The board approved the purchase with Dr. Diwan abstaining. TheraCour, also controlled by Dr. Diwan, charged $2.403 million of development and other costs in FY2015; the license provides for a 15% royalty on future licensed-product net sales.
Outlook, risks and contingencies
Management said available cash could fund budgeted operations for more than 24 months; elsewhere the filing estimates runway through March 31, 2017 or June 30, 2017. The filing also states that current funds do not cover the full business plan and that additional financing will be needed beyond the runway. Management estimated an additional $10–15 million for development of eye-drop, oral FluCide and DengueCide candidates over 36–48 months, and outlined approximately $24 million of planned cash costs over 24 months, including R&D, overhead, capital expenditure and clinical-trial spending. These are estimates, not committed funding.
Management aimed to file one or possibly two IND applications, with a filing targeted late in FY2016, subject to preclinical results, manufacturing scale-up, facility validation, regulatory requirements and outside collaborators. The company reported promising animal and cell-culture findings, including FluCide rat safety screening and HerpeCide animal results, but cautioned that the findings were preliminary and do not establish human safety or efficacy. The Ebola program was moved to a background priority after the epidemic eased. No commercial revenue timing can be reliably projected.
- Development and regulatory risk: candidates may fail in further studies, clinical trials or regulatory review; none had entered human trials at the reporting date.
- Funding and dilution risk: ongoing losses, clinical development costs and capital needs could require further debt or equity financing. Convertible debentures, warrants and preferred shares create potential dilution and complex accounting.
- Manufacturing and execution risk: the new facility required validation and reproducible production processes; the company reported prior delays of more than 18 months and continuing dependence on contract research organizations.
- Control and related-party risk: a material weakness arose from insufficient personnel with expertise to account for non-routine transactions such as derivatives. Remediation steps had not operated long enough to demonstrate effectiveness. The company is also dependent on related-party licensor TheraCour.
- Other risks: competition, intellectual-property protection, key-person dependence, uncertain market acceptance and stock-price volatility. The filing reports no material pending legal proceedings.
Most important facts for investors to verify
- Whether the derivative-related restatements and the reported $8.529 million fair-value gain are correctly understood and reconciled to the audited statements.
- Whether the internal-control material weakness has been remediated, and whether the accounting team and review procedures can reliably handle derivatives and other complex transactions.
- Actual cash runway and committed funding: the filing gives differing runway dates and says cash supports current operations, but not the complete development plan.
- Progress toward validated, reproducible clinical-material production, IND submissions and any subsequent human trials; assess these against management’s timelines and preliminary-evidence caveats.
- Terms, repayment and conversion risks of the $11 million Series B and Series C debentures, related derivative liabilities, potential share issuance and the director’s creditor position.
- Related-party arrangements and concentration of dependence on TheraCour, including its development charges, royalty terms and ownership ties to the chairman.